European Union - English - EMA (European Medicines Agency)

sanofi b.v. - alglucosidase alfa - glycogen storage disease type ii - other alimentary tract and metabolism products, - myozyme is indicated for long-term enzyme-replacement therapy (ert) in patients with a confirmed diagnosis of pompe disease (acid-α-glucosidase deficiency).in patients with late-onset pompe disease the evidence of efficacy is limited.

Malta - English - Medicines Authority

laboratoire aguettant 1 rue alexander fleming, 69007 lyon, france - norepinephrine - concentrate for solution for infusion - norepinephrine 2 mg/ml - cardiac therapy

Malta - English - Medicines Authority

laboratoire aguettant 1 rue alexander fleming, 69007 lyon, france - noradrenaline acid, tartrate - concentrate for solution for infusion - noradrenaline acid tartrate 2 mg/ml - cardiac therapy

United States - English - NLM (National Library of Medicine)

genzyme corporation - alglucosidase alfa (unii: dti67o9503) (alglucosidase alfa - unii:dti67o9503) - alglucosidase alfa 5 mg in 1 ml - lumizyme® (alglucosidase alfa) [see description (11)] is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with pompe disease (acid α-glucosidase [gaa] deficiency). none. risk summary data from postmarketing reports and published case reports with alglucosidase alfa use in pregnant women have not identified a lumizyme-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. the continuation of treatment for pompe disease during pregnancy should be individualized to the pregnant woman. untreated pompe disease may result in worsening disease symptoms in pregnant women [see clinical considerations] . reproduction studies performed in mice and rabbits at doses resulting in exposures up to 0.4 or 0.5 times the human steady-state auc (area under the plasma concentration-time curve), respectively, during the period of organogenesis revealed no evidence of effects on embryo-fetal development. in mice there was an increase in pup mortality during lactation

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - glucose, quantity: 500 mg/ml - injection, intravenous infusion - excipient ingredients: hydrochloric acid; water for injections; sodium bicarbonate - glucose 50% intravenous infusion is strongly hypertonic and may be used to reduce increased cerebrospinal pressure and/or oedema due to delirium tremens or acute alcoholic intoxication. it may also be used to treat severe hypoglycaemia due to an excess of insulin and to provide concentrated calories in total parenteral nutrition regimes.

Kenya - English - Pharmacy and Poisons Board

questa care inc. c/o surgilinks ltd 4251 s. higuera st. suite 800 san luis obispo ca - glucose iv infusion bp - infusion - glucose iv infusion bp 5%w/v - other i.v. solution additives

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.25 mmol/l glucose 1.5 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.25 mmol/l glucose 2.3 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.25 mmol/l glucose 4.25 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.75 mmol/l glucose 1.5 % (w/v) - blood substitutes and perfusion solutions